Inaugural HBM+ drug report provides roadmap to sustainable, accessible health care
Drug Trends and Strategic Insights report Toronto, ON (Sept. 15, 2020) – As COVID-19 continues to impact the Canadian economy and strain health care resources, these times call for a critical re-think of health care services and benefit plans, with a focus on adopting rigorously-tested solutions that increase the value of drug spend. With these industry realities front of mind, health benefits manager HBM+ is today releasing its inaugural Drug Trends and Strategic Insights report, which presents drug claims and utilization data for HBM+ partner insurers and third party administrators (TPAs), representing over two million claimants and over $1.5 billion in annual adjudicated drug costs. The report examines the latest drug directions and trends, including the use of opioids, biosimilars, and the evolving approaches to reimbursing health care professionals, as well as tangible cost management and health improvement solutions for plan sponsors and advisors. It also provides a glimpse of the future, including the impact of pharmacogenomics, an exciting field that offers the potential to personalize the way drugs are prescribed and ultimately improve outcomes, and calls for the consideration of gene therapy strategies as these expensive new treatments emerge in the health care landscape. “We are relentless at pursuing...